Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

111.00EUR
2:31pm IST
Change (% chg)

€-1.30 (-1.16%)
Prev Close
€112.30
Open
€112.50
Day's High
€112.55
Day's Low
€110.70
Volume
78,089
Avg. Vol
579,633
52-wk High
€125.95
52-wk Low
€76.22

Select another date:

Fri, Jul 10 2020

BRIEF-Merck Announces Opening M Lab Collaboration Center In Shanghai

* MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES OPENING OF ITS LIFE SCIENCE BUSINESS' LARGEST M LAB™ COLLABORATION CENTER IN SHANGHAI Source text for Eikon: Further company coverage: (Berlin Speed Desk)

Exclusive: EU secures potential COVID-19 drugs from Roche, Germany's Merck - source

BRUSSELS The European Commission has struck deals with drugmakers Roche and Merck KGaA to secure supplies of experimental treatments for COVID-19, a Commission source told Reuters on Wednesday.

Exclusive: EU secures potential COVID-19 drugs from Roche, Germany's Merck

BRUSSELS The European Commission has struck deals with drugmakers Roche and Merck KGaA to secure supplies of experimental treatments for COVID-19, a Commission source told Reuters on Wednesday.

EXCLUSIVE-EU secures potential COVID-19 drugs from Roche, Germany's Merck - source

* EU also in talks to buy vaccines, remdesivir (Adds comment from Roche, details about trials)

EXCLUSIVE-EU reaches deals with Roche, Merck for supply of COVID-19 drugs - source

BRUSSELS, July 8 The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday.

EXCLUSIVE-EU reaches deals with Roche, Merck for supply of COVID-19 drugs - source

BRUSSELS, July 8 The European Commission has reached agreements with pharmaceutical companies Roche and Merck KGaA to supply experimental drugs that can be used to treat COVID-19 patients, a commission source told Reuters on Wednesday.

Sigma-Aldrich, not Merck gave misleading info in deal review, EU says

BRUSSELS U.S. drugmaker Sigma-Aldrich provided incorrect and misleading information during an antitrust review of its 2015 takeover by Merck KGaA , EU regulators said on Wednesday as they dropped the German company from their investigation.

Sigma-Aldrich, not Merck gave misleading info in deal review, EU says

BRUSSELS, July 1 U.S. drugmaker Sigma-Aldrich provided incorrect and misleading information during an antitrust review of its 2015 takeover by Merck KGaA, EU regulators said on Wednesday as they dropped the German company from their investigation.

BRIEF-Merck Receives Additional EU Statement In Proceedings Concerning Sigma-Aldrich Acquisition

* RECEIVES EU COMMISSION SUPPLEMENTARY STATEMENT OF OBJECTIONS IN THE PROCEEDINGS CONCERNING THE SIGMA-ALDRICH ACQUISITION

BRIEF-Merck KGaA: First Clinical Trial Of TLR7 And 8 Inhibitor As Treatment For Covid-19 Symptoms

* INITIATES FIRST CLINICAL TRIAL OF TLR7 AND 8 INHIBITOR AS A POTENTIAL TREATMENT FOR SEVERE SYMPTOMS OF COVID-19 INFECTION

Select another date: